Exelixis’ Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain and Narcotic A

		Cancer Friends Network > Types of Cancer > Bone Cancer
Exelixis’ Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain and Narcotic A

LinkBack

Thread Tools

Display Modes

#1 (permalink)

11-13-2011, 05:17 PM

cancerfr

Administrator

Join Date: Sep 2008

Posts: 47,337

Exelixis’ Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain and Narcotic A

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases. Howard Scher, M.D., chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center, will present the data on ...

Tim Pearson

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On Forum Rules

All times are GMT. The time now is 07:35 AM.

CancerFriends.net